Thermo Fisher Scientific Inc. $TMO Stock Holdings Lifted by YHB Investment Advisors Inc.

YHB Investment Advisors Inc. increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,988 shares of the medical research company’s stock after acquiring an additional 1,182 shares during the quarter. Thermo Fisher Scientific accounts for about 1.6% of YHB Investment Advisors Inc.’s holdings, making the stock its 14th largest position. YHB Investment Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $24,561,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its holdings in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after purchasing an additional 988 shares during the period. Revolve Wealth Partners LLC grew its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. Darwin Wealth Management LLC acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at approximately $170,000. Raymond James Financial Inc. boosted its stake in shares of Thermo Fisher Scientific by 7.4% during the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock valued at $315,781,000 after buying an additional 53,542 shares during the period. Finally, California State Teachers Retirement System grew its holdings in shares of Thermo Fisher Scientific by 0.4% during the 2nd quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after acquiring an additional 2,262 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $596.65 on Friday. The firm has a market capitalization of $220.61 billion, a PE ratio of 32.10, a PEG ratio of 2.45 and a beta of 0.85. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The firm’s fifty day simple moving average is $527.07 and its 200 day simple moving average is $509.02.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same period in the prior year, the company earned $4.28 earnings per share. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 10.11%.

Wall Street Analyst Weigh In

TMO has been the subject of several recent research reports. Piper Sandler increased their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a report on Monday, July 27th. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Jefferies Financial Group reiterated a “buy” rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Finally, Morgan Stanley raised their price objective on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $619.41.

Insider Buying and Selling

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 5,850 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $580.00, for a total value of $3,393,000.00. Following the completion of the sale, the vice president directly owned 14,784 shares of the company’s stock, valued at $8,574,720. This represents a 28.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. The trade was a 1.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 52,053 shares of company stock valued at $30,643,589 in the last ninety days. Company insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.